S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Scotts Miracle-Gro Hits Bottom, Reversal In Play
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Altria is a Great Recession Stock, Long-Term Outlook Uncertain
Closing prices for crude oil, gold and other commodities
NASDAQ:SRNE

Sorrento Therapeutics - SRNE Stock Forecast, Price & News

$0.96
0.00 (0.00%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.92
▼
$0.98
50-Day Range
$0.74
▼
$1.38
52-Week Range
$0.74
▼
$3.60
Volume
16.08 million shs
Average Volume
11.34 million shs
Market Capitalization
$453.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Sorrento Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
837.5% Upside
$9.00 Price Target
Short Interest
Bearish
13.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.05
Upright™ Environmental Score
News Sentiment
0.75mentions of Sorrento Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.84) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

614th out of 1,053 stocks

Biological Products, Except Diagnostic Industry

97th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

SRNE stock logo

About Sorrento Therapeutics (NASDAQ:SRNE) Stock

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Stock News Headlines

January 14, 2023 | marketbeat.com
MarketBeat: Week in Review 01/09-01/13 (SRNE)
Markets are looking for direction in early trading before a holiday weekend. Here are some of the popular stories MarketBeat analysts were covering this week.
January 12, 2023 | marketbeat.com
Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
Sorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to market
February 2, 2023 | Investing Trends (Ad)
The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
February 2, 2023 | americanbankingnews.com
HC Wainwright Weighs in on Sorrento Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:SRNE)
February 2, 2023 | americanbankingnews.com
Sorrento Therapeutics (NASDAQ:SRNE) Price Target Cut to $13.00
January 31, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Sorrento Therapeutics (SRNE), Aethlon Medical (AEMD)
January 29, 2023 | finance.yahoo.com
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
January 29, 2023 | finance.yahoo.com
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
February 2, 2023 | Investing Trends (Ad)
The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
January 17, 2023 | reuters.com
SRNE.A - | Stock Price & Latest News | Reuters
January 9, 2023 | finance.yahoo.com
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
January 2, 2023 | nz.finance.yahoo.com
Sorrento Therapeutics, Inc. (SRNE)
December 6, 2022 | finance.yahoo.com
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
December 5, 2022 | finance.yahoo.com
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
November 29, 2022 | seekingalpha.com
Sorrento posts Phase 1 data for oral COVID therapy
November 29, 2022 | finance.yahoo.com
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
November 18, 2022 | finance.yahoo.com
Further weakness as Sorrento Therapeutics (NASDAQ:SRNE) drops 12% this week, taking one-year losses to 76%
November 13, 2022 | tmcnet.com
Sorrento to Host Webcast to Discuss Newly Presented
November 13, 2022 | finance.yahoo.com
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
November 10, 2022 | finance.yahoo.com
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
November 10, 2022 | finance.yahoo.com
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”
November 9, 2022 | seekingalpha.com
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits
November 9, 2022 | apnews.com
Sorrento Therapeutics: Q3 Earnings Snapshot
November 8, 2022 | seekingalpha.com
Sorrento Therapeutics: Down The Rabbit Hole
October 28, 2022 | finance.yahoo.com
7 of the Best Contrarian Stocks to Buy When Investors Are Fearful
October 21, 2022 | finance.yahoo.com
Sorrento Therapeutics, Inc. stock performance and analyst projections
October 20, 2022 | finance.yahoo.com
Why Sorrento Therapeutics Stock Is on the Rise Today
See More Headlines
Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
CUSIP
N/A
CIK
850261
Web
www.sorrentotherapeutics.com
Phone
(858) 203-4100
Fax
858-210-3759
Employees
799
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,202.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-428,330,000.00
Net Margins
-818.22%
Pretax Margin
-877.48%
Return on Equity
-282.82%
Return on Assets
-57.64%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
0.88
Quick Ratio
0.79

Sales & Book Value

Annual Sales
$52.90 million
Price / Sales
8.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.26 per share
Price / Book
3.69

Miscellaneous

Outstanding Shares
471,880,000
Free Float
459,611,000
Market Cap
$453.00 million
Optionable
Optionable
Beta
1.95

Key Executives

  • Henry H. Ji
    Chairman, President & Chief Executive Officer
  • Shawn Sahebi
    Senior Vice President-Commercial Operations
  • Elizabeth Adkins Czerepak
    Chief Financial Officer & Executive Vice President
  • Mike A. Royal
    Chief Medical Officer
  • Robert D. Allen
    Senior Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SRNE Stock - Frequently Asked Questions

Should I buy or sell Sorrento Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRNE shares.
View SRNE analyst ratings or view top-rated stocks.

What is Sorrento Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 12-month target prices for Sorrento Therapeutics' stock. Their SRNE share price forecasts range from $5.00 to $13.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 837.5% from the stock's current price.
View analysts price targets for SRNE or view top-rated stocks among Wall Street analysts.

How have SRNE shares performed in 2023?

Sorrento Therapeutics' stock was trading at $0.8860 on January 1st, 2023. Since then, SRNE shares have increased by 8.4% and is now trading at $0.96.
View the best growth stocks for 2023 here.

When is Sorrento Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our SRNE earnings forecast.

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) announced its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biopharmaceutical company had revenue of $17.40 million for the quarter, compared to analyst estimates of $11.69 million. Sorrento Therapeutics had a negative net margin of 818.22% and a negative trailing twelve-month return on equity of 282.82%.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mayo Clinic (0.06%), Donald L. Hagan LLC (0.04%), Collective Family Office LLC (0.03%), GoalVest Advisory LLC (0.01%), Weaver Consulting Group (0.01%) and Bank of Montreal Can (0.00%). Insiders that own company stock include Henry Ji, Kim Janda and Robin L Smith.
View institutional ownership trends.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $0.96.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $453.00 million and generates $52.90 million in revenue each year.

How many employees does Sorrento Therapeutics have?

The company employs 799 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759.

This page (NASDAQ:SRNE) was last updated on 2/2/2023 by MarketBeat.com Staff